WO2020144646A1 - Apalutamide dispersée dans de la compote de pomme pour traiter le cancer de la prostate - Google Patents

Apalutamide dispersée dans de la compote de pomme pour traiter le cancer de la prostate Download PDF

Info

Publication number
WO2020144646A1
WO2020144646A1 PCT/IB2020/050192 IB2020050192W WO2020144646A1 WO 2020144646 A1 WO2020144646 A1 WO 2020144646A1 IB 2020050192 W IB2020050192 W IB 2020050192W WO 2020144646 A1 WO2020144646 A1 WO 2020144646A1
Authority
WO
WIPO (PCT)
Prior art keywords
apalutamide
study
prostate cancer
treatment
administered
Prior art date
Application number
PCT/IB2020/050192
Other languages
English (en)
Inventor
Dr. Caly CHIEN
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of WO2020144646A1 publication Critical patent/WO2020144646A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des compositions pharmaceutiques et des procédés de traitement du cancer de la prostate, notamment du cancer de la prostate résistant à la castration, du cancer de la prostate résistant à la castration métastatique et du cancer de la prostate résistant à la castration non métastatique, avec un produit médicamenteux approuvé contenant un anti-androgène choisi dans le groupe constitué par l'enzalutamide, l'apalutamide et la darolutamide.
PCT/IB2020/050192 2019-01-10 2020-01-10 Apalutamide dispersée dans de la compote de pomme pour traiter le cancer de la prostate WO2020144646A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962790567P 2019-01-10 2019-01-10
US201962790561P 2019-01-10 2019-01-10
US201962790574P 2019-01-10 2019-01-10
US201962790566P 2019-01-10 2019-01-10
US62/790,574 2019-01-10
US62/790,566 2019-01-10
US62/790,567 2019-01-10
US62/790,561 2019-01-10

Publications (1)

Publication Number Publication Date
WO2020144646A1 true WO2020144646A1 (fr) 2020-07-16

Family

ID=69326578

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/IB2020/050197 WO2020144650A1 (fr) 2019-01-10 2020-01-10 Anti-androgènes pour le traitement du cancer de la prostate
PCT/IB2020/050193 WO2020144647A1 (fr) 2019-01-10 2020-01-10 Composition pharmaceutique comprenant de l'apalutamide dispersé dans une compote de pomme
PCT/IB2020/050196 WO2020144649A1 (fr) 2019-01-10 2020-01-10 Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme
PCT/IB2020/050192 WO2020144646A1 (fr) 2019-01-10 2020-01-10 Apalutamide dispersée dans de la compote de pomme pour traiter le cancer de la prostate

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/IB2020/050197 WO2020144650A1 (fr) 2019-01-10 2020-01-10 Anti-androgènes pour le traitement du cancer de la prostate
PCT/IB2020/050193 WO2020144647A1 (fr) 2019-01-10 2020-01-10 Composition pharmaceutique comprenant de l'apalutamide dispersé dans une compote de pomme
PCT/IB2020/050196 WO2020144649A1 (fr) 2019-01-10 2020-01-10 Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme

Country Status (1)

Country Link
WO (4) WO2020144650A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062927A1 (fr) * 2009-11-17 2011-05-26 Novartis Ag Méthode de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r
WO2014043208A1 (fr) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations d'enzalutamide
WO2014113260A1 (fr) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Modulateur du récepteur des androgènes et ses utilisations
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
WO2016090105A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
WO2016090098A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anti-cancéreuses
WO2016090101A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402036B2 (en) 2011-10-17 2016-07-26 Rudolph Technologies, Inc. Scanning operation with concurrent focus and inspection
US20190209469A1 (en) * 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
AU2018351714A1 (en) * 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062927A1 (fr) * 2009-11-17 2011-05-26 Novartis Ag Méthode de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r
WO2014043208A1 (fr) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations d'enzalutamide
US20140100256A1 (en) 2012-09-11 2014-04-10 Bend Research Formulations of enzalutamide
WO2014113260A1 (fr) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Modulateur du récepteur des androgènes et ses utilisations
WO2016090105A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
WO2016090098A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anti-cancéreuses
WO2016090101A1 (fr) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
US20170360707A1 (en) 2014-12-05 2017-12-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
US20170360754A1 (en) 2014-12-05 2017-12-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
US20170360713A1 (en) 2014-12-05 2017-12-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Remington - The Science, and Practice of Pharmacy", 2005
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
AJN MARCH: "Putting the Meds in the Applesauce Is hiding medicine in food ever ethically justified?", AMERICAN JOURNAL OF NURSING., vol. 112, no. 3, 1 January 2012 (2012-01-01), US, pages 67 - 69, XP055675996, ISSN: 0002-936X *
ANONYMOUS: "A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants - Full Text View - ClinicalTrials.gov", 14 January 2019 (2019-01-14), XP055676113, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03802682> [retrieved on 20200312] *
ANONYMOUS: "Prescribing Information for ERLEADA", 1 January 2018 (2018-01-01), XP055676002, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210951s001lbl.pdf> [retrieved on 20200312] *
ANONYMOUS: "Use of Liquids and/or Soft Foods as Vehicles for Drug Administration: General Considerations for Selection and In Vitro Methods for Product Quality Assessments Guidance for Industry", 13 July 2018 (2018-07-13), XP055676101, Retrieved from the Internet <URL:https://www.fda.gov/media/114872/download> [retrieved on 20200312] *
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 915087-27-3
CLEGG ET AL., CANCER RES., vol. 72, 15 March 2012 (2012-03-15), pages 1494
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
J CLIN ONCOL, vol. 11, no. 8, 1993, pages 1566 - 72
MATSUBARA, N.MUKAI, H.HOSONO, A. ET AL., CANCER CHEMOTHER PHARMACAL, vol. 80, 2017, pages 1063
SCIENCE, vol. 324, no. 5928, 8 May 2009 (2009-05-08), pages 787 - 90
VADIM S. KOSHKIN ET AL: "Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials", THERAPEUTIC ADVANCES IN UROLOGY FEB 2013, vol. 10, no. 12, 14 December 2018 (2018-12-14), pages 445 - 454, XP055676141, ISSN: 1756-2872, DOI: 10.1177/1756287218811450 *

Also Published As

Publication number Publication date
WO2020144647A1 (fr) 2020-07-16
WO2020144650A1 (fr) 2020-07-16
WO2020144649A1 (fr) 2020-07-16

Similar Documents

Publication Publication Date Title
US11160796B2 (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US20200353057A1 (en) Reducing immunogenicity to pegloticase
AU2019306828A1 (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
KR20210153038A (ko) 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
WO2020144646A1 (fr) Apalutamide dispersée dans de la compote de pomme pour traiter le cancer de la prostate
US11723898B2 (en) Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2019074536A1 (fr) Méthodes de traitement du cancer de la prostate par administration d&#39;acétate d&#39;abiratérone et de prednisone avec une thérapie par privation androgénique
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
WO2024006406A1 (fr) Inhibiteurs thérapeutiques de tyrosine kinase pour le traitement de la sclérose en plaques et de la myasthénie gravis
Jean-Francois et al. The GlaxoSmithKline group of companies DB2113208

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20702363

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10.11.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 20702363

Country of ref document: EP

Kind code of ref document: A1